Pegylated liposomal doxorubicin, 5-fluorouracil and cisplatin versus mitomycin-C, 5-fluorouracil and cisplatin for advanced gastric cancer: a randomized phase II trial

Stefano Cascinu (1) , Eva Galizia (2) , Roberto Labianca (3) , Francesco Ferraù (4) , Francesca Pucci (5) , Rosa Rita Silva (2) , Gabriele Luppi (6) , Giordano Domenico Beretta (7) , Rossana Berardi (1) , Mario Scartozzi (1)

1 Clinica di Oncologia Medica, AO Ospedali Riuniti
2 Oncologia Medica
3 Oncologia Medica
4 Oncologia Medica
5 Oncologia Medica
6 U.O. di Oncologia e di Radiologia I^, Policlinico
7 U.O. Oncologia Ospedale "Sant'Orsola Fatebenefratelli"

Mots clés: Advanced gastric cancer; Pegylated liposomal doxorubicin; Metastatic gastric cancer; Cisplatin-5FU-containing regimen

Stefano Cascinu, Eva Galizia, Roberto Labianca, Francesco Ferraù, Francesca Pucci, et al.. Pegylated liposomal doxorubicin, 5-fluorouracil and cisplatin versus mitomycin-C, 5-fluorouracil and cisplatin for advanced gastric cancer: a randomized phase II trial. Cancer Chemotherapy and Pharmacology, 2010, 68 (1), pp.37-43. ⟨10.1007/s00280-010-1424-8⟩. ⟨hal-00619931⟩